Representative Results:

Characterisation of hESCs maintained prior to hepatic differentiation
In order to characterise the stem cell status of the H9 hESCs used in the study we studied a number of parameters. The cells exhibited hESC morphology, small, tightly packed cells growing in defined colonies ( Figure 1A ) and expressed the pluripotent stem cell gene markers, Oct-3/4 and Nanog ( Figure 1B ). We did not find significant differences in the expression of these genes compared to a H7 hESC line positive control. Additionally, 90.1% of the hESCs population was positive for the stem cell marker SSEA-4 ( Figure 1C ).
hESC differentiation to hepatic endoderm
Human embryonic stem cells can be efficiently differentiated to hepatic endoderm in vitro . At day 9 of differentiation, cells were harvested and differentiation of hESC to HLCs was assessed. As previously reported the hESCs exhibited a series of profound morphological changes, and by day 9, exhibited early hepatocyte morphology developing a polygonal appearance ( Figure 2A ). Moreover, downregulation of Oct-3/4 over the 9 day time course was observed ( Figure 2B ). In contrast, liver transcripts AFP and albumin were up-regulated ( Figure 2C ) from day 7 onwards.
In vitro maturation of Hepatic Endoderm
Hepatic endoderm was matured in vitro using the established procedure ( We have developed a simple, homogeneous and highly reproducible in vitro model to generate scalable levels of human HLCs. Our model has been validated by a number of external collaborating laboratories. We routinely characterise stem cell derived HLCs using our in house tool box of developmental markers and liver specific functional assays (most of which are commercially available). The critical stages in our process are: the maintenance of stem cell pluripotency; the ability to direct stem cell differentiation to definitive endoderm; the specification of homogeneous cultures of hepatic endoderm and the ability to derive mature hepatic endoderm exhibiting broad range function in vitro.
One limitation to the large scale deployment of the stem cell derived HLC technology has been the short term differentiated function of mature hepatic endoderm in culture (˜4 days on matrigel). As such we have screened a polymer library for bio-active and novel cellular supports. This has led to the identification of a novel support which maintains hepatic function for at least 15 days. The future directions for this technology are initially industrial application in the drug discovery process . Mid term gains form this technology are likely to be humanised extra-corporeal liver support devices for bridging or treating patients with liver disease. Long term gains from this technology could in cell based transplantation therapy for liver disease, however the current data demonstrates that this strategy requires significant effort before it can be used safely in the clinic (Payne et al 2011).
In conclusion, the significance of our in vitro technology is the ability to generate homogeneous and limitless cultures of high fidelity human HLCs for applied biology.
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